Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.
CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.
The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.
CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.
The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.
CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.
Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.
CONMED Corporation (NYSE: CNMD) is set to release its fourth quarter 2022 financial results on February 2, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the outcomes. Participants can pre-register for the call or access a live webcast on CONMED's website. The company specializes in surgical devices for minimally invasive procedures across various medical fields. The press release includes forward-looking statements regarding the impact of the COVID-19 pandemic on the business and operating volumes.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED Corporation (NYSE: CNMD) announced participation in the 34th Annual Piper Sandler Healthcare Conference, with a fireside chat led by Curt R. Hartman and Todd W. Garner on November 30, 2022, at 3:30 p.m. ET. A live audio webcast will be available on the 'Investors' section of their website and will be replayed afterward. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery. For more details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has withdrawn its full-year 2022 financial outlook due to unexpected shipping disruptions caused by new warehouse management software implementation. The backlog peaked at $35 million but has now decreased to $28 million. Despite these challenges, daily shipment volumes have returned to normal, and the company anticipates limited impact on fourth-quarter performance. For 2023, CNMD expects revenue between $1.170 billion and $1.230 billion, with adjusted diluted net earnings per share projected between $3.20 and $3.50.
CONMED Corporation (NYSE: CNMD) announced participation in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:15 p.m. ET. Key executives, including Curt R. Hartman, Chair and CEO, and Todd W. Garner, CFO, will represent the company. Interested parties can access a live audio webcast through the company’s website, which will also offer a replay after the event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) reported a strong Q3 2022 with sales of $275.1 million, a 10.6% increase year-over-year. Domestic revenue surged by 14.2%, while international revenue grew 6.2%. Diluted net earnings per share rose to $1.48 from $0.47 a year prior, although adjusted diluted EPS fell 3.8% to $0.77. The company has narrowed its full-year revenue guidance to between $1.1 billion and $1.115 billion, reflecting a 150 to 180 bps negative impact from foreign exchange. The recent acquisition of Biorez is expected to contribute positively to revenue growth.
CONMED Corporation (NYSE: CNMD) will release its third-quarter 2022 financial results on October 26, 2022, post market close. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day. Interested parties can participate via telephone by pre-registering online or access the webcast from CONMED's website, with a replay available after the call.
CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties.
CONMED Corporation (NYSE: CNMD) announced participation in the 20th Annual Morgan Stanley Global Healthcare Conference. The fireside chat featuring Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, CFO, is scheduled for September 13, 2022, at 5:15 p.m. ET. A live audio webcast will be accessible via the Company’s website, with a replay available post-event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties. For more information, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2022, to shareholders on record as of September 15, 2022. This financial move reinforces the company's commitment to returning value to its shareholders. CONMED specializes in surgical devices and equipment for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has finalized its acquisition of Biorez, Inc., a medical device start-up in New Haven, CT, specializing in soft tissue healing through the BioBrace® Implant technology. This innovative device aims to reinforce weak soft tissues and facilitate healing. The acquisition is funded through CONMED's existing credit facility, underscoring its commitment to enhancing its product offerings in the medical technology sector.
FAQ
What is the current stock price of CONMED Corporation (CNMD)?
What is the market cap of CONMED Corporation (CNMD)?
What does CONMED Corporation specialize in?
Where is CONMED Corporation headquartered?
How many employees does CONMED Corporation have?
What are the main product specialties of CONMED Corporation?
What are the primary reporting units of CONMED Corporation?
In which regions does CONMED Corporation generate most of its revenue?
What is the mission of CONMED Corporation?
How does CONMED Corporation ensure customer and patient satisfaction?
What recent achievements has CONMED Corporation made?
What is CONMED Corporation's approach to innovation?
